Home » Stocks » ACAD

ACADIA Pharmaceuticals Inc. (ACAD)

Stock Price: $53.28 USD -1.45 (-2.65%)
Updated December 3, 4:00 PM EST - Market closed

ACAD Stock Price Chart

Key Info

Market Cap 8.47B
Revenue (ttm) 419.07M
Net Income (ttm) -267.86M
Shares Out 158.13M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $53.28
Previous Close $54.73
Change ($) -1.45
Change (%) -2.65%
Day's Open 54.88
Day's Range 52.88 - 55.45
Day's Volume 1,088,086
52-Week Range 31.65 - 57.00

ACAD Stock News

24/7 Wall Street - 18 hours ago

The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.

Other stocks mentioned: CVS, HR, QURE
Zacks Investment Research - 6 days ago

Let's see if Acadia Healthcare (ACHC) stock is a good choice for value-oriented investors right now from multiple angles.

Other stocks mentioned: ACHC
Seeking Alpha - 2 weeks ago

ACADIA Pharmaceuticals Inc.'s (ACAD) Management Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)

Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3...

Zacks Investment Research - 4 weeks ago

ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid.

The Motley Fool - 4 weeks ago

The good news? Sales of Nuplazid are soaring.

Seeking Alpha - 4 weeks ago

ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Steve Davis on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 weeks ago

Acadia (ACAD) delivered earnings and revenue surprises of -42.11% and 1.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 4 weeks ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet me...

Zacks Investment Research - 1 month ago

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Other stocks mentioned: ALNY, AVRO, BHVN, BNTX
The Motley Fool - 1 month ago

The company's latest quarterly update impressed investors.

Other stocks mentioned: ACHC
Zacks Investment Research - 1 month ago

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insider Monkey - 1 month ago

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-r...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of th...

Forbes - 1 month ago

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...

Other stocks mentioned: ALKS, NBIX, ARWR, BMRN, IONS
Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of Directors. Dr. Garofalo is a biopharm...

Seeking Alpha - 2 months ago

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Steve Davis Presents at Cantor Virtual Global Healthcare Conference (Transcript)

Seeking Alpha - 2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

Other stocks mentioned: MS
PRNewsWire - 2 months ago

SAN DIEGO, Sept. 5, 2020 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ACADIA Pharmaceuticals Inc.

Zacks Investment Research - 2 months ago

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

InvestorPlace - 3 months ago

Spot the best cheap stocks to buy under $5 with the right catalyst at the right time, and it could lead to your next double-digit opportunity. The post 3 Cheap Stocks to Buy for Under $5 Now ...

Other stocks mentioned: APPS, BGFV
Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences: Citi 15th Annual BioPhar...

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr.

Zacks Investment Research - 3 months ago

ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chroni...

Business Wire - 3 months ago

SAN DIEGO & FORT WORTH, Texas--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with w...

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m.

Zacks Investment Research - 3 months ago

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

Seeking Alpha - 3 months ago

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet me...

Newsfile Corp - 4 months ago

San Diego, California--(Newsfile Corp. - July 31, 2020) - If you would like to discuss your legal rights email leo@barrlaw.com or call (619) 780-3993.

Business Wire - 4 months ago

SANTA MARIA, Calif. & SAN DIEGO--(BUSINESS WIRE)---- $ACAD--Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc.

Zacks Investment Research - 4 months ago

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

WASHINGTON & ATLANTA & SAN DIEGO--(BUSINESS WIRE)--UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qual...

Zacks Investment Research - 4 months ago

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

Forbes - 4 months ago

The performance of the healthcare sector has been mixed this year. While dental and surgery-related stocks have declined - as Covid-19 impacts sectors that require a close person to person con...

Other stocks mentioned: ALXN, NVCR
Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020, after the close of the...

Investors Business Daily - 4 months ago

Acadia Pharmaceuticals said Tuesday its experimental depression treatment failed in a Phase 3 study — prompting ACAD stock to plunge. That put shares near their lowest point this month.

24/7 Wall Street - 4 months ago

The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID...

Other stocks mentioned: CTSO, GNW, HIBB, IBM, LLNW, NBEV, QIWI, TNXP
Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S.

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, p...

Investors Business Daily - 4 months ago

Acadia Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stock Upgrades: Acadia Pharmaceuticals Shows Rising Relative Strength...

Seeking Alpha - 4 months ago

With the three sNDA approvals in the next three years, the share price is set to soar.

The Motley Fool - 5 months ago

While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.

Other stocks mentioned: YMAB
Seeking Alpha - 5 months ago

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Hosts 2020 Annual Meeting of Stockholders (Transcript)

Zacks Investment Research - 5 months ago

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

24/7 Wall Street - 5 months ago

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Other stocks mentioned: BIIB, BTAI, CRTX, ITCI, NBIX, SAGE, ZYNE
Seeking Alpha - 5 months ago

Under every scenario below, it is possible for investors to see a positive investment return.

Zacks Investment Research - 5 months ago

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

About ACAD

ACADIA Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment f... [Read more...]

Industry
Biotechnology
IPO Date
May 27, 2004
CEO
Stephen Davis
Employees
580
Stock Exchange
NASDAQ
Ticker Symbol
ACAD
Full Company Profile

Financial Performance

In 2019, ACAD's revenue was $339.08 million, an increase of 51.50% compared to the previous year's $223.81 million. Losses were -$235.26 million, -4.05% less than in 2018.

Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is 59.61, which is an increase of 11.88% from the latest price.

Price Target
$59.61
(11.88% upside)
Analyst Consensus: Buy